Take a Virtual Tour of Genomic Testing & Research Laboratory
We're proud to offer you a behind-the-scenes virtual tour of the new Glioblastoma Foundation Genomic Testing & Research Laboratory!
This groundbreaking Lab aims to revolutionize glioblastoma treatment by giving patients greater access to comprehensive genomic testing services, as well as identifying drugs specific for their tumors.
Glioblastoma is the most aggressive and lethal form of brain cancer, with a median survival rate of just 12 to 18 months. Because each patient’s glioblastoma is totally unique to them, uniform standards of care fail to have long-term effectiveness.
The goal of the Glioblastoma Foundation’s new Genomic Testing & Research Laboratory is to offer state-of-the-art molecular testing services to patients to inform personalized treatment plans to improve survival and quality of life. The Glioblastoma Foundation aims to make these services available at a low cost, with the goal of significantly improving outcomes for those receiving what is now a devastating diagnosis.
The state-of-the-art Genomic Testing & Research Laboratory, located in Durham, NC, will be equipped to receive tumor tissue samples from all over the US, and provide prompt test results starting this Fall.
Explore the Glioblastoma Foundation Genomic Testing and Research Laboratory in 3D
Each year, approximately 15,000 people are diagnosed with glioblastoma. For more information about the Glioblastoma Foundation and the new Genomic Testing & Research Laboratory, please visit https://www.glioblastomafoundation.org/
About the Glioblastoma Foundation:
The Glioblastoma Foundation, established in 2016, aims to transform glioblastoma treatment and care through research, advocacy, and support initiatives. By funding innovative research projects, raising awareness, and providing resources for patients and families, the Glioblastoma Foundation strives to improve outcomes and quality of life for those affected by this aggressive form of brain cancer.
©2024 Glioblastoma Foundation. All rights reserved.